210 related articles for article (PubMed ID: 21083242)
1. Addressing metabolite safety during first-in-man studies using ¹⁴C-labeled drug and accelerator mass spectrometry.
Lappin G; Seymour M
Bioanalysis; 2010 Jul; 2(7):1315-24. PubMed ID: 21083242
[TBL] [Abstract][Full Text] [Related]
2. Obtaining exposures of metabolites in preclinical species through plasma pooling and quantitative NMR: addressing metabolites in safety testing (MIST) guidance without using radiolabeled compounds and chemically synthesized metabolite standards.
Vishwanathan K; Babalola K; Wang J; Espina R; Yu L; Adedoyin A; Talaat R; Mutlib A; Scatina J
Chem Res Toxicol; 2009 Feb; 22(2):311-22. PubMed ID: 19067650
[TBL] [Abstract][Full Text] [Related]
3. Which human metabolites have we MIST? Retrospective analysis, practical aspects, and perspectives for metabolite identification and quantification in pharmaceutical development.
Leclercq L; Cuyckens F; Mannens GS; de Vries R; Timmerman P; Evans DC
Chem Res Toxicol; 2009 Feb; 22(2):280-93. PubMed ID: 19183054
[TBL] [Abstract][Full Text] [Related]
4. New ultrasensitive detection technologies and techniques for use in microdosing studies.
Lappin G; Wagner CC; Langer O; van de Merbel N
Bioanalysis; 2009 May; 1(2):357-66. PubMed ID: 21083172
[TBL] [Abstract][Full Text] [Related]
5. Metabolites in safety testing.
Robison TW; Jacobs A
Bioanalysis; 2009 Oct; 1(7):1193-200. PubMed ID: 21083045
[TBL] [Abstract][Full Text] [Related]
6. Accelerator MS: its role as a frontline bioanalytical technique.
Seymour MA
Bioanalysis; 2011 Dec; 3(24):2817-23. PubMed ID: 22185281
[TBL] [Abstract][Full Text] [Related]
7. Meeting the MIST regulations: human metabolism in Phase I using AMS and a tiered bioanalytical approach.
Lappin G; Seymour M; Gross G; Jørgensen M; Kall M; Kværnø L
Bioanalysis; 2012 Feb; 4(4):407-16. PubMed ID: 22394141
[TBL] [Abstract][Full Text] [Related]
8. Liquid chromatography/atmospheric pressure ionization-mass spectrometry in drug metabolism studies.
Kostiainen R; Kotiaho T; Kuuranne T; Auriola S
J Mass Spectrom; 2003 Apr; 38(4):357-72. PubMed ID: 12717747
[TBL] [Abstract][Full Text] [Related]
9. High-resolution isotope-dilution mass spectrometry using metabolism of isotope-labeled compounds: application to drug metabolites.
Vrbanac JJ; Hilgers A; Dubnicka T; Shilliday FB; Humphries D; Hayes RN
Rapid Commun Mass Spectrom; 2012 Nov; 26(22):2569-76. PubMed ID: 23059872
[TBL] [Abstract][Full Text] [Related]
10. The impact of recent innovations in the use of liquid chromatography-mass spectrometry in support of drug metabolism studies: are we all the way there yet?
Nassar AE; Talaat RE; Kamel AM
Curr Opin Drug Discov Devel; 2006 Jan; 9(1):61-74. PubMed ID: 16445118
[TBL] [Abstract][Full Text] [Related]
11. HPLC/ICP-MS in combination with "reverse" online isotope dilution in drug metabolism studies.
Meermann B; Hulstaert A; Laenen A; Van Looveren C; Vliegen M; Cuyckens F; Vanhaecke F
Anal Chem; 2012 Mar; 84(5):2395-401. PubMed ID: 22304524
[TBL] [Abstract][Full Text] [Related]
12. Comparison of a 250 kV single-stage accelerator mass spectrometer with a 5 MV tandem accelerator mass spectrometer--fitness for purpose in bioanalysis.
Young GC; Corless S; Felgate CC; Colthup PV
Rapid Commun Mass Spectrom; 2008 Dec; 22(24):4035-42. PubMed ID: 19009519
[TBL] [Abstract][Full Text] [Related]
13. A safer method for studying hormone metabolism in an Asian elephant (Elephas maximus): accelerator mass spectrometry.
Yon L; Faulkner B; Kanchanapangka S; Chaiyabutr N; Meepan S; Lasley B
Zoo Biol; 2010; 29(6):760-6. PubMed ID: 20127658
[TBL] [Abstract][Full Text] [Related]
14. Applications of accelerator mass spectrometry for pharmacological and toxicological research.
Brown K; Tompkins EM; White IN
Mass Spectrom Rev; 2006; 25(1):127-45. PubMed ID: 16059873
[TBL] [Abstract][Full Text] [Related]
15. Practical experience of using human microdosing with AMS analysis to obtain early human drug metabolism and PK data.
Garner RC
Bioanalysis; 2010 Mar; 2(3):429-40. PubMed ID: 21083253
[TBL] [Abstract][Full Text] [Related]
16. Approaches to the assessment of stable and chemically reactive drug metabolites in early clinical trials.
Baillie TA
Chem Res Toxicol; 2009 Feb; 22(2):263-6. PubMed ID: 19216579
[TBL] [Abstract][Full Text] [Related]
17. Microdosing: a valuable tool for accelerating drug development and the role of bioanalytical methods in meeting the challenge.
Ings RM
Bioanalysis; 2009 Oct; 1(7):1293-305. PubMed ID: 21083052
[TBL] [Abstract][Full Text] [Related]
18. Quantitating isotopic molecular labels with accelerator mass spectrometry.
Vogel JS; Love AH
Methods Enzymol; 2005; 402():402-22. PubMed ID: 16401517
[TBL] [Abstract][Full Text] [Related]
19. Nuclear magnetic resonance spectroscopy as a quantitative tool to determine the concentrations of biologically produced metabolites: implications in metabolites in safety testing.
Espina R; Yu L; Wang J; Tong Z; Vashishtha S; Talaat R; Scatina J; Mutlib A
Chem Res Toxicol; 2009 Feb; 22(2):299-310. PubMed ID: 18980340
[TBL] [Abstract][Full Text] [Related]
20. Accelerator mass spectrometry allows for cellular quantification of doxorubicin at femtomolar concentrations.
DeGregorio MW; Dingley KH; Wurz GT; Ubick E; Turteltaub KW
Cancer Chemother Pharmacol; 2006 Feb; 57(3):335-42. PubMed ID: 16047147
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
